SureTrader
Home > Boards > US Listed > Biotechs >

BioLineRx Ltd. (BLRX)

BLRX RSS Feed
Add BLRX Price Alert      Hide Sticky   Hide Intro
Moderator: midastouch017, BooDog
Search This Board: 
Last Post: 1/15/2018 11:21:27 AM - Followers: 96 - Board type: Free - Posts Today: 0

BIOLINERX
BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel.
The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.

BioLineRx's close ties with universities, research institutes, academic institutions, technology transfer offices and biotechnology companies, both in Israel and globally, enable access to promising projects at an early stage. The first stage involves a stringent selection process. BioLineRx's scientists specialize in evaluating potential drug candidates from both scientific and marketing perspectives. After acquiring the most promising projects, the Company then performs feasibility assessment studies and development through pre-clinical and clinical stages. Supported and assisted by a distinguished panel of scientific advisers, the Company's scientists and experts in pharmacy and regulation, clinical trials and IP work together to advance BioLineRx’s pipeline usually through Phase II proof of concept in humans. And finally, the Company partners with medium size and large pharmaceutical companies to complete the clinical development and bring the product to market.
 
BioLineRx also operates BioLine Innovations Jerusalem (BIJ) a biotechnology incubator for the development of pre-clinical therapeutic candidates, and an Early Development Program (EDP) dedicated to identifying and advancing promising early stage programs.

==============================

HIGHLIGHTS:: BioLineRx Ltd.(BLRX)

BL-7040 (IBD) – Received positive results from a Phase 2 proof-of-concept study to evaluate the effectiveness of BL-7040 for the treatment of inflammatory bowel disease (IBD)

Immediate next steps include evaluating the most advantageous ways to progress with this therapeutic candidate from a clinical and business perspective, including examining potential additional indications. Plans also include accelerating discussions with potential co-development and licensing partners.

BL-8040 (AML) – Received U.S. regulatory approvals to commence a Phase 2a trial for the treatment of relapsed/refractory acute myeloid leukemia (AML); trial to be conducted at three sites in the U.S. and five sites in Israel, with initial patient enrollment expected in Q2 2013; partial results expected in Q4 2013 and final results expected in the second half of 2014

BL-1040 (ventricular remodeling) – Recruitment commenced at U.S. sites for the PRESERVATION I clinical trial, a CE Mark registration trial for BL-1040 (BCM), a novel medical device for the prevention of ventricular remodeling following an acute myocardial infarction; there are currently multiple active sites recruiting in six countries

BL-5010 (skin lesions) – Reached final stages of development for proprietary pen-like applicator for BL-5010, a novel formulation of two acids being developed for the non-surgical removal of skin lesions; planning to commence pivotal CE-Mark registration trial for European approval in the second half of 2013

BL-8020 (HCV) – Commenced a Phase 1/2 clinical trial to evaluate the effectiveness of an orally-available, interferon-free treatment for Hepatitis C (HCV) at two sites in France, following approval from the French regulatory authorities; partial results expected in Q4 2013; final results expected in the first half of 2014

BL-1020 (schizophrenia) – Disappointing results of interim analysis for the Phase 2/3 CLARITY trial led to termination of the trial; full unblinded study data is expected during Q3 2013

BL-9010 (severe asthma) – Added a novel, bi-specific antibody for the treatment of severe and persistent asthma to the main therapeutic pipeline, following promising pre-clinical data

Capital Raise – $8 million direct equity placement to the OrbiMed Group was completed in February 2013


“In the past few months, we have seen major progress on a number of clinical and pre-clinical programs in our pipeline, which offer exciting opportunities to address unmet medical needs in a wide range of therapeutic areas. We believe our active programs offer significant potential for patients around the world, as well as for the future success of our Company and its shareholders,” stated Kinneret Savitsky, Ph.D, Chief Executive Officer of BioLineRx. “In the third quarter of this year, we expect to receive a full analysis of the unblinded study data for all participants in the CLARITY Phase 2/3 trial for BL-1020. While we discontinued this clinical trial in mid-March based on disappointing results of the interim analysis, we will not decide the future of the overall BL-1020 program until we have carried out a more thorough review of the full unblinded results.”

“The PRESERVATION I study being conducted by our partner, Ikaria, for BL-1040, for the treatment of ventricular remodeling post-AMI, is moving forward at full steam, with multiple sites in six countries around the world actively recruiting, including a number of sites in the U.S. BL-1040 remains one of our leading compounds, with significant clinical data expected to be reported next year, and we hope that it will eventually offer a great benefit to heart attack patients,” continued Dr. Savitsky.

“We continue to accelerate development of our clinical pipeline, with three of our compounds completing significant milestones since the beginning of the year. Our BL-7040 compound for IBD completed a Phase 2a open-label, proof-of-concept study with very encouraging and positive results. We are now evaluating next steps for BL-7040 in order to identify the best way to move forward from both a clinical and business perspective, including examining potential additional indications. In parallel, we are also planning to accelerate discussions with potential co-development and licensing partners for this asset.”

“In addition, BL-8040, for hematological cancers, one of our most exciting programs, just received FDA approval to commence a Phase 2a trial for the treatment of relapsed/refractory AML. We are excited to initiate this multicenter, open-label study under an IND, which will be conducted in the U.S. and Israel, and will enroll up to 50 patients. MD Anderson Cancer Center in Houston will be the initial site for this trial, with two additional premier sites in the US and five other well-known sites in Israel expected to participate. We believe the excitement surrounding the trial, especially at these particular sites, is a testament to the need for an AML therapy, as well as the potential of BL-8040 shown in the previous pre-clinical and clinical data.”

“Finally, we recently reported enrollment of the first patient in our Phase 1/2 trial for BL-8020, an oral treatment for HCV, at a leading hospital in Paris, France. We look forward to partial results from the trial in the fourth quarter of 2013, as well as final results in the first half of 2014. I would also like to point out that as our pipeline evolves, we continue to replenish our pre-clinical pipeline with the addition of promising assets, such as BL-9010 for the treatment of severe and persistent asthma, which recently graduated from our Early Development Program,” concluded Dr. Savitsky



Link To Interview with BioLineRX VP Of Business Development:
http://www.pharmatelevision.com/Video/1176-PTVNRDavidMalek.aspx



biolinerx.com -  BioLineRX Website




SureTrader
BLRX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BLRX News: Report of Foreign Issuer (6-k) 12/28/2017 04:34:55 PM
BLRX News: Securities Registration (foreign Private Issuer) (f-3) 12/28/2017 04:34:29 PM
BLRX News: Report of Foreign Issuer (6-k) 12/21/2017 07:01:13 AM
BLRX News: BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple ... 12/21/2017 07:00:00 AM
BLRX News: Amended Statement of Ownership (sc 13g/a) 12/14/2017 06:04:42 AM
PostSubject
#1708   What an unusual mid day drop you guys Dizzle96 01/15/18 11:21:27 AM
#1707   These clinical trials have been going on since Dizzle96 01/15/18 11:19:04 AM
#1706   And I was afraid it w gonna take TAB78 01/13/18 01:30:38 PM
#1705   Quite a scavenger you are. midastouch017 01/12/18 01:38:23 PM
#1704   Welp that was a quick run lol All the Dizzle96 01/12/18 12:51:09 PM
#1703   I guess I missed some news, we are TAB78 01/12/18 10:25:16 AM
#1702   Good writeup from Seeking Alpha. Looks like a tsoprano-1 01/11/18 10:15:48 AM
#1701   Yeah, sure, good for you! midastouch017 01/11/18 06:22:47 AM
#1700   I'm thinking we're seeing some deeper collaborations within BooDog 01/11/18 05:45:14 AM
#1699   This is all insider trading Dizzle96 01/10/18 07:01:01 PM
#1698   Are we at $3 yet ? Lol Dizzle96 01/10/18 07:00:07 PM
#1697   I'm still winning ! Dizzle96 01/10/18 06:59:50 PM
#1696   As a long you admittedly lost, as a midastouch017 01/10/18 04:16:51 PM
#1695   Decent volume. Thinking someone's getting squeezed. BooDog 01/10/18 03:53:28 PM
#1694   Lol, what a joke. You're kidding, right? midastouch017 01/10/18 01:51:24 PM
#1693   Not even double the volume helps. Head scratcher Dizzle96 01/10/18 10:32:50 AM
#1692   Lot of dumping today Dizzle96 01/10/18 10:31:24 AM
#1691   Lot of red trades . Father Time is catching Dizzle96 01/08/18 03:36:49 PM
#1690   I'll make sure to have a faster ride Dizzle96 01/08/18 03:35:35 PM
#1689   Any idea when the abstract for ASCO will BarrellofHay 01/08/18 01:40:36 PM
#1688   Thanks BD - I did not see it Amatuer17 01/05/18 07:04:17 PM
#1687   I think the following of $BLRX is starting BooDog 01/05/18 02:23:37 PM
#1686   With more than X 4 average volume midastouch017 01/05/18 02:18:39 PM
#1685   Some nice action today. New money? BooDog 01/05/18 02:12:24 PM
#1684   Shorts, keep the lubricant ready!!! midastouch017 01/05/18 12:00:43 PM
#1683   Yes, not an unfamiliar story. Till they go BooDog 01/04/18 10:55:09 PM
#1682   Wait for iiiiiiit ........... Dizzle96 01/04/18 02:08:36 PM
#1681   Unfortunately , in this stock, it won't happen. Dizzle96 01/04/18 02:08:11 PM
#1680   Not hard to forget about these. Until BooDog 01/03/18 09:38:13 AM
#1678   Yup sounds like the same old song. Dizzle96 01/03/18 09:34:42 AM
#1677   They're priming big time for the next 3 BooDog 12/29/17 12:11:30 PM
#1676   Are we at $3 yet? When will you take Dizzle96 12/29/17 11:46:05 AM
#1675   This is a turd of a stock You take Dizzle96 12/29/17 11:45:14 AM
#1674   There's a huge gap, in fact the gap Dizzle96 12/29/17 11:42:13 AM
#1673   Bvf Inc increased its stake in Biolinerx Ltd midastouch017 12/29/17 09:09:48 AM
#1672   On December 28, 2017, the Company filed a BooDog 12/29/17 07:55:53 AM
#1671   Too early to read these filings. Looks BooDog 12/29/17 07:24:43 AM
#1670   And they screw up with big shelf Amatuer17 12/29/17 06:42:04 AM
#1669   Decent outlook Amatuer17. I have a strategy BooDog 12/28/17 08:30:47 AM
#1668   Actually this is going to be slow mover Amatuer17 12/28/17 08:19:05 AM
#1667   Take a look at the chart. See the BooDog 12/27/17 07:32:34 PM
#1666   I've only started buying. Good luck with your short. BooDog 12/27/17 07:06:23 PM
#1664   That guy is going to sit on those Dizzle96 12/27/17 06:30:25 PM
#1663   Market did well today !!!!! (Except for BLRX). Nice Dizzle96 12/27/17 06:28:27 PM
#1662   That should make the squeeze all the more better. $BLRX BooDog 12/26/17 05:10:46 AM
#1661   Lmao. This turd is a waste. Not worth Rogerthat1 12/24/17 12:31:10 AM
#1660   Yup and the same has been said for Dizzle96 12/22/17 07:09:42 PM
#1659   Looking good for next week. Even if it BooDog 12/22/17 04:37:09 PM
#1658   Just a wee bit to get through 1.15/1.16. BooDog 12/22/17 11:55:00 AM
#1657   Expect a slight dip in 2020? I'm BooDog 12/21/17 04:20:46 PM
PostSubject